Overview

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.

Phase:

PHASE2

Details

Lead Sponsor:

BioXcel Therapeutics Inc

Collaborator:

Premier Research Group plc

Treatments:

Dexmedetomidine